admin, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Numinus Congratulates MAPS on its Phase 3 Study Results Published in...

Numinus Takes Actions to Accelerate its Path to Profitability by Focusing...

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

Clearmind Medicine Closes US$2.25 Million Public Offering

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate...

PT442 – Burning Questions About Burning Man: Mud, Ebola, and the...

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted...

Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving...

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

BetterLife Pharma to Host Investors Update Call on September 18, 2023

1...454647...218 Page 46 of 218

EDITOR PICKS

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin